A groundbreaking Harvard study reveals that semaglutide could benefit more people in the U.S. than ever imagined.

As revolutionary new weight-loss drugs turn consumers off ultraprocessed foods, the industry is on the hunt for new products.

"Since more than half of U.S. adults who have taken GLP-1 receptor agonists state the therapy was difficult to afford, ...